This Core resource will provide comprehensive biostatistics consultation and collaboration to all projects inthe proposed P01. In addition, it wi II provide support for data storage and computing, and assist with theidentification and solution of complex data tasks arising in the course of project activities. Core members willwork with project investigators across a wide spectrum of activities, encompassing data acquisition (includingstudy design, feasibility of objectives, and sample size issues), data quality control (preprocessing of data forerrors), data analysis (including visualization, biostatistical modeling, and assistance with manuscriptwriting), and development of innovative customized biostatistics methodologies and tools if required byspecific projects. The proposed Biostatistics Core will be housed in the Division of Clinical Trials andBiometry of the Department of Oncology, an active and committed group of biostatistics and bioinformaticsfaculty members and staff, with access to state-of-the art equipment and a broad range of expertise. ThisCore resource is the continuation of an existing resource within the original and current P01 program atJohns Hopkins. Core members have a strong commitment to this P01, stemming from a history ofcollaboration with the investigators of this as well as other related projects. All proposed projects areanticipated to make use of this resource in every aim.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA070970-10A1
Application #
7355833
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Project Start
2007-12-01
Project End
2012-11-30
Budget Start
2007-12-01
Budget End
2009-01-31
Support Year
10
Fiscal Year
2008
Total Cost
$78,996
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Gamper, Christopher J; Takemoto, Clifford M; Chen, Allen R et al. (2016) High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. J Pediatr Hematol Oncol 38:627-635
Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79
Sharrow, Allison C; Perkins, Brandy; Collector, Michael I et al. (2016) Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy. Gynecol Oncol 142:341-8
Kim, MinJung; Tan, Yee Sun; Cheng, Wen-Chih et al. (2015) MIR144 and MIR451 regulate human erythropoiesis via RAB14. Br J Haematol 168:583-97
Candia, Julián; Cherukuri, Srujana; Guo, Yin et al. (2015) Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach. Converg Sci Phys Oncol 1:
Brodsky, Robert A (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124:2804-11
Rau, Rachel; Magoon, Daniel; Greenblatt, Sarah et al. (2014) NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. Exp Hematol 42:101-13.e5
Tan, Yee Sun; Kim, MinJung; Kingsbury, Tami J et al. (2014) Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia. PLoS One 9:e111777
Ma, Hayley S; Nguyen, Bao; Duffield, Amy S et al. (2014) FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 74:5206-17
Belet, Stefanie; Fieremans, Nathalie; Yuan, Xuan et al. (2014) Early frameshift mutation in PIGA identified in a large XLID family without neonatal lethality. Hum Mutat 35:350-5

Showing the most recent 10 out of 60 publications